
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3736867/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effect of vitamin D supplementation during pregnancy on maternal and neonatal outcomes: a systematic review and meta-analysis of randomized controlled trials. Fertility and Sterility, 2015, 103, 1278-1288.e4.	0.5	234
2	Depressive disorders and the menopause transition. Maturitas, 2012, 71, 120-130.	1.0	172
3	Gender Differences in Cardiovascular Disease: Hormonal and Biochemical Influences. Reproductive Sciences, 2010, 17, 511-531.	1.1	155
4	Effects of the Mediterranean diet on longevity and age-related morbid conditions. Maturitas, 2009, 64, 67-79.	1.0	151
5	Cardiovascular risk in menopausal women and prevalent related co-morbid conditions: facing the post-Women's Health Initiative era. Fertility and Sterility, 2009, 92, 1171-1186.	0.5	125
6	Insulin resistance and endometrial cancer risk: AÂsystematic review and meta-analysis. European Journal of Cancer, 2015, 51, 2747-2758.	1.3	122
7	Assessment of sexuality among middle-aged women using the Female Sexual Function Index. Climacteric, 2009, 12, 213-221.	1.1	116
8	Effect of exercise on sleep quality and insomnia in middle-aged women: A systematic review and meta-analysis of randomized controlled trials. Maturitas, 2017, 100, 49-56.	1.0	107
9	Firstâ€ŧrimester maternal serum 25â€hydroxyvitamin D ₃ status and pregnancy outcome. International Journal of Gynecology and Obstetrics, 2012, 116, 6-9.	1.0	105
10	The Role of Vitamin D in Fertility and during Pregnancy and Lactation: A Review of Clinical Data. International Journal of Environmental Research and Public Health, 2018, 15, 2241.	1.2	101
11	Vitamin D: The secosteroid hormone and human reproduction. Gynecological Endocrinology, 2007, 23, 13-24.	0.7	97
12	EMAS position statement: Vitamin D and postmenopausal health. Maturitas, 2012, 71, 83-88.	1.0	95
13	Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement. Maturitas, 2017, 101, 23-30.	1.0	94
14	Vitamin D and aging: Beyond calcium and bone metabolism. Maturitas, 2011, 69, 27-36.	1.0	85
15	EMAS position statement: Management of uterine fibroids. Maturitas, 2014, 79, 106-116.	1.0	85
16	Vitamin D and its implications for musculoskeletal health in women: An update. Maturitas, 2007, 58, 117-137.	1.0	84
17	Vitamin D testing: advantages and limits of the current assays. European Journal of Clinical Nutrition, 2020, 74, 231-247.	1.3	81
18	EMAS position statement: The ten point guide to the integral management of menopausal health. Maturitas, 2015, 81, 88-92.	1.0	76

#	Article	IF	CITATIONS
19	Circulating leptin, resistin, adiponectin, visfatin, adipsin and ghrelin levels and insulin resistance in postmenopausal women with and without the metabolic syndrome. Maturitas, 2014, 79, 86-90.	1.0	75
20	Osteosarcopenic obesity and fall prevention strategies. Maturitas, 2015, 80, 126-132.	1.0	71
21	EMAS position statement: Non-hormonal management of menopausal vasomotor symptoms. Maturitas, 2015, 81, 410-413.	1.0	70
22	Assessment of sexual function and related factors in mid-aged sexually active Spanish women with the six-item Female Sex Function Index. Menopause, 2012, 19, 1224-1230.	0.8	68
23	Maintaining postreproductive health: A care pathway from the European Menopause and Andropause Society (EMAS). Maturitas, 2016, 89, 63-72.	1.0	67
24	Perceived stress, insomnia and related factors in women around the menopause. Maturitas, 2012, 72, 367-372.	1.0	66
25	Assessment of sexual function of mid-aged Ecuadorian women with the 6-item Female Sexual Function Index. Maturitas, 2012, 71, 407-412.	1.0	64
26	EMAS clinical guide: Low-dose vaginal estrogens for postmenopausal vaginal atrophy. Maturitas, 2012, 73, 171-174.	1.0	63
27	Obesity is Related to Increased Menopausal Symptoms among Spanish Women. Menopause International, 2010, 16, 105-110.	1.6	62
28	Assessing predictors of sexual function in mid-aged sexually active women. Maturitas, 2011, 68, 387-390.	1.0	62
29	Coronavirus disease 2019 and gender-related mortality in European countries: A meta-analysis. Maturitas, 2020, 141, 59-62.	1.0	62
30	Factors related to insomnia and sleepiness in the late third trimester of pregnancy. Archives of Gynecology and Obstetrics, 2012, 286, 55-61.	0.8	61
31	Factors relating to insomnia during the menopausal transition as evaluated by the Insomnia Severity Index. Maturitas, 2011, 69, 157-161.	1.0	59
32	Lichen sclerosus in women: a review. Climacteric, 2017, 20, 339-347.	1.1	59
33	Effect of exercise alone or combined with dietary supplements on anthropometric and physical performance measures in community-dwelling elderly people with sarcopenic obesity: A meta-analysis of randomized controlled trials. Maturitas, 2018, 116, 24-35.	1.0	56
34	Sexual function, satisfaction with life and menopausal symptoms in middle-aged women. Maturitas, 2013, 75, 261-269.	1.0	55
35	Radioimmunoassay of Arginine Vasopressin in Rhesus Monkey Plasma. Endocrinology, 1976, 98, 975-981.	1.4	54
36	Effects of programmed exercise on depressive symptoms in midlife and older women: A meta-analysis of randomized controlled trials. Maturitas, 2017, 106, 38-47.	1.0	54

#	Article	IF	CITATIONS
37	EMAS position statement: Testosterone replacement therapy in the aging male― Maturitas, 2016, 84, 94-99.	1.0	53
38	Severe menopausal symptoms in middle-aged women are associated to female and male factors. Archives of Gynecology and Obstetrics, 2010, 281, 879-885.	0.8	51
39	Depressive Symptoms and Resilience among Pregnant Adolescents: A Case-Control Study. Obstetrics and Cynecology International, 2010, 2010, 1-7.	0.5	47
40	EMAS clinical guide: Assessment of the endometrium in peri and postmenopausal women. Maturitas, 2013, 75, 181-190.	1.0	46
41	lodine and thyroid hormones during pregnancy and postpartum. Gynecological Endocrinology, 2007, 23, 414-428.	0.7	45
42	Angiogenesis, inflammation and endothelial function in postmenopausal women screened for the metabolic syndrome. Maturitas, 2014, 77, 370-374.	1.0	45
43	Resilience, depressed mood, and menopausal symptoms in postmenopausal women. Menopause, 2014, 21, 159-164.	0.8	44
44	An evaluation of the contents and quality of menopause information on the World Wide Web. Maturitas, 2004, 49, 276-282.	1.0	42
45	Vitamin D metabolism and cardiovascular risk factors in postmenopausal women. Maturitas, 2009, 62, 248-262.	1.0	42
46	Osteoporosis management in patients with breast cancer: EMAS position statement. Maturitas, 2017, 95, 65-71.	1.0	42
47	Assessing the content and quality of information on the treatment of postmenopausal osteoporosis on the World Wide Web. Gynecological Endocrinology, 2006, 22, 669-675.	0.7	41
48	Sexual Function Assessment in Postmenopausal Women with the 14â€Item Changes in Sexual Functioning Questionnaire. Journal of Sexual Medicine, 2011, 8, 2144-2151.	0.3	41
49	Obesity-related insulin resistance in adolescents: a systematic review and meta-analysis of observational studies. Gynecological Endocrinology, 2017, 33, 179-184.	0.7	41
50	EMAS recommendations for conditions in the workplace for menopausal women. Maturitas, 2016, 85, 79-81.	1.0	40
51	Depressive symptoms in climacteric women are related to menopausal symptom intensity and partner factors. Climacteric, 2009, 12, 395-403.	1.1	39
52	Bone Mass Gain During Puberty and Adolescence: Deconstructing Gender Characteristics. Current Medicinal Chemistry, 2010, 17, 453-466.	1.2	39
53	Life satisfaction, loneliness and related factors during female midlife. Maturitas, 2012, 72, 88-92.	1.0	39
54	EMAS position statement: Diet and health in midlife and beyond. Maturitas, 2013, 74, 99-104.	1.0	39

#	Article	IF	CITATIONS
55	Management of pudendal neuralgia. Climacteric, 2014, 17, 654-656.	1.1	39
56	Exercise alone or combined with dietary supplements for sarcopenic obesity in community-dwelling older people: A systematic review of randomized controlled trials. Maturitas, 2018, 110, 92-103.	1.0	39
57	First Trimester Serum 25-Hydroxyvitamin D Status and Factors Related to Lower Levels in Gravids Living in the Spanish Mediterranean Coast. Reproductive Sciences, 2011, 18, 730-736.	1.1	38
58	Soy isoflavones improve insulin sensitivity without changing serum leptin among postmenopausal women. Climacteric, 2012, 15, 611-620.	1.1	38
59	Sleep disturbance, obesity, physical fitness and quality of life in older women: EXERNET study group. Climacteric, 2017, 20, 72-79.	1.1	38
60	Association between sexual function and depression in sexually active, mid-aged, Peruvian women. Climacteric, 2011, 14, 654-660.	1.1	37
61	Nutrition and health during mid-life: searching for solutions and meeting challenges for the aging population. Climacteric, 2013, 16, 85-95.	1.1	36
62	<i>Vaccinium macrocarpon</i> : An interesting option for women with recurrent urinary tract infections and other health benefits. Journal of Obstetrics and Gynaecology Research, 2009, 35, 630-639.	0.6	35
63	Systematic review and meta-analysis of the effect of metformin treatment on overall mortality rates in women with endometrial cancer and type 2 diabetes mellitus. Maturitas, 2017, 101, 6-11.	1.0	34
64	EMAS clinical guide: Vulvar lichen sclerosus in peri and postmenopausal women. Maturitas, 2013, 74, 279-282.	1.0	33
65	Feto-placental nitric oxide, asymmetric dimethylarginine and vascular endothelial growth factor (VEGF) levels and VEGF gene polymorphisms in severe preeclampsia. Journal of Maternal-Fetal and Neonatal Medicine, 2013, 26, 226-232.	0.7	33
66	Assessment of sleep quality and correlates in a large cohort of Colombian women around menopause. Menopause, 2013, 20, 464-469.	0.8	33
67	Effects of preeclampsia and eclampsia on maternal metabolic and biochemical outcomes in later life: a systematic review and meta-analysis. Metabolism: Clinical and Experimental, 2020, 102, 154012.	1.5	33
68	Assessment of subjective sleep disturbance and related factors during female mid-life with the Jenkins Sleep Scale. Maturitas, 2014, 77, 344-350.	1.0	32
69	Sexual Dysfunction Risk and Associated Factors in Young Peruvian University Women. Journal of Sexual Medicine, 2011, 8, 1701-1709.	0.3	30
70	Why sex matters: the biological mechanisms of cardiovascular disease. Gynecological Endocrinology, 2012, 28, 746-751.	0.7	30
71	Vitamin D supplementation during pregnancy: an overview. Current Opinion in Obstetrics and Gynecology, 2020, 32, 316-321.	0.9	30
72	The polycystic ovary syndrome and gynecological cancer risk. Gynecological Endocrinology, 2020, 36, 289-293.	0.7	30

FAUSTINO R PéREZ-LÃ³PEZ

#	Article	IF	CITATIONS
73	Pro-inflammatory cytokine levels in postmenopausal women with the metabolic syndrome. Gynecological Endocrinology, 2011, 27, 685-691.	0.7	29
74	Postmenopausal osteoporosis and alendronate. Maturitas, 2004, 48, 179-192.	1.0	28
75	Insulin growth factor (IGF) 1, IGF-binding proteins and ovarian cancer risk: A systematic review and meta-analysis. Maturitas, 2016, 94, 22-29.	1.0	28
76	Temporal Patterns of Vasopressin Release Following Electrical Stimulation of the Amygdala and the Neuroendocrine Pathway in the Monkey. Neuroendocrinology, 1977, 23, 61-75.	1.2	26
77	Effect of combined spinal–epidural analgesia versus epidural analgesia on labor and delivery duration. International Journal of Gynecology and Obstetrics, 2011, 114, 246-250.	1.0	26
78	Vitamin D Acquisition and Breast Cancer Risk. Reproductive Sciences, 2009, 16, 7-19.	1.1	25
79	Assessment of insomnia and related risk factors in postmenopausal women screened for the metabolic syndrome. Maturitas, 2013, 74, 154-159.	1.0	25
80	GONADOTROPHIN HORMONE RELEASING TESTS IN WOMEN RECEIVING HORMONAL CONTRACEPTION. Clinical Endocrinology, 1975, 4, 477-485.	1.2	24
81	<i>Cimicifuga racemosa</i> treatment and health related quality of life in post-menopausal Spanish women. Gynecological Endocrinology, 2009, 25, 21-26.	0.7	24
82	Factors related to increased daytime sleepiness during the menopausal transition as evaluated by the Epworth Sleepiness Scale. Maturitas, 2010, 65, 75-80.	1.0	24
83	Peri- and post-menopausal incidental adnexal masses and the risk of sporadic ovarian malignancy: new insights and clinical management. Gynecological Endocrinology, 2010, 26, 631-643.	0.7	24
84	Assessment of sexuality after hysterectomy using the Female Sexual Function Index. Journal of Obstetrics and Gynaecology, 2012, 32, 180-184.	0.4	24
85	Maternal serum cytokine levels in pregnancies complicated with threatened preterm labour. Gynecological Endocrinology, 2017, 33, 408-412.	0.7	24
86	The effect of endometriosis on sexual function as assessed with the Female Sexual Function Index: systematic review and meta-analysis. Gynecological Endocrinology, 2020, 36, 1015-1023.	0.7	24
87	A model of care for healthy menopause and ageing: EMAS position statement. Maturitas, 2016, 92, 1-6.	1.0	23
88	Metabolic syndrome during female midlife: what are the risks?. Climacteric, 2019, 22, 127-132.	1.1	23
89	Misoprostol combined with cervical single or double balloon catheters versus misoprostol alone for labor induction of singleton pregnancies: a meta-analysis of randomized trials. Journal of Maternal-Fetal and Neonatal Medicine, 2020, 33, 3453-3468.	0.7	23
90	Chagas disease in pregnancy: a non-endemic problem in a globalized world. Archives of Gynecology and Obstetrics, 2010, 282, 595-599.	0.8	22

#	Article	IF	CITATIONS
91	Iron and vitamin status biomarkers and its association with physical fitness in adolescents: the HELENA study. Journal of Applied Physiology, 2012, 113, 566-573.	1.2	22
92	Nitric oxide and pro-inflammatory cytokine serum levels in postmenopausal women with the metabolic syndrome. Gynecological Endocrinology, 2012, 28, 787-791.	0.7	22
93	Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials. Maturitas, 2019, 129, 12-22.	1.0	22
94	Management of postmenopausal vulvovaginal atrophy: recommendations of the International Society for the Study of Vulvovaginal Disease. Gynecological Endocrinology, 2021, 37, 746-752.	0.7	22
95	Polymorphisms of the methylenetetrahydrofolate reductase gene (C677T and A1298C) in nulliparous women complicated with preeclampsia. Gynecological Endocrinology, 2014, 30, 392-396.	0.7	21
96	Diagnosis and management of vulvodynia in postmenopausal women. Maturitas, 2018, 108, 84-94.	1.0	21
97	Assessment of self-esteem in mid-aged women. Maturitas, 2010, 66, 77-82.	1.0	20
98	Quality of life in a large cohort of mid-aged Colombian women assessed using the Cervantes Scale. Menopause, 2012, 19, 924-930.	0.8	20
99	EMAS position statement: Individualized breast cancer screening versus population-based mammography screening programmes. Maturitas, 2014, 79, 481-486.	1.0	20
100	Perinatal outcome in singleton pregnancies complicated with preeclampsia and eclampsia in Ecuador. Journal of Obstetrics and Gynaecology, 2016, 36, 581-584.	0.4	20
101	Vitamin D supplementation after the menopause. Therapeutic Advances in Endocrinology and Metabolism, 2020, 11, 204201882093129.	1.4	20
102	Urinary incontinence, related factors and menopause-related quality of life in mid-aged women assessed with the Cervantes Scale. Maturitas, 2012, 73, 369-372.	1.0	19
103	Prevalence of insomnia and related factors in a large mid-aged female Colombian sample. Maturitas, 2013, 74, 346-351.	1.0	19
104	Assessment of menopause-related symptoms in mid-aged women with the 10-item Cervantes Scale. Maturitas, 2013, 76, 151-154.	1.0	19
105	Fall prevention in postmenopausal women: the role of Pilates exercise training. Climacteric, 2016, 19, 229-233.	1.1	19
106	Single versus double-balloon catheters for the induction of labor of singleton pregnancies: a meta-analysis of randomized and quasi-randomized controlled trials. Archives of Gynecology and Obstetrics, 2018, 297, 1089-1100.	0.8	19
107	Clinical manifestations and evaluation of postmenopausal vulvovaginal atrophy. Gynecological Endocrinology, 2021, 37, 740-745.	0.7	19
108	Effect of programmed exercise on insulin sensitivity in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials. Menopause, 2017, 24, 1404-1413.	0.8	18

#	Article	IF	CITATIONS
109	The effect of programmed exercise over anxiety symptoms in midlife and older women: a meta-analysis of randomized controlled trials. Climacteric, 2018, 21, 123-131.	1.1	18
110	Effectiveness of the cervical pessary for the prevention of preterm birth in singleton pregnancies with a short cervix: a meta-analysis of randomized trials. Archives of Gynecology and Obstetrics, 2019, 299, 1215-1231.	0.8	18
111	Association of female genital mutilation and female sexual dysfunction: A systematic review and meta-analysis. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2020, 254, 236-244.	0.5	18
112	Obstetric and perinatal outcomes of pregnancies with COVID 19: a systematic review and meta-analysis. Journal of Maternal-Fetal and Neonatal Medicine, 2022, 35, 9742-9758.	0.7	18
113	Associations between obesity, physical fitness, and urinary incontinence in non-institutionalized postmenopausal women: The elderly EXERNET multi-center study. Maturitas, 2015, 82, 208-214.	1.0	17
114	Resilience and related factors in urban, mid-aged Spanish women. Climacteric, 2015, 18, 867-872.	1.1	17
115	Assessing sexual problems in women at midlife using the short version of the female sexual function index. Maturitas, 2015, 82, 299-303.	1.0	17
116	Circulating kisspeptin and anti-müllerian hormone levels, and insulin resistance in women with polycystic ovary syndrome: A systematic review, meta-analysis, and meta-regression. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2021, 260, 85-98.	0.5	17
117	Risk of Development of Vulvar Cancer in Women With Lichen Sclerosus or Lichen Planus: A Systematic Review. Journal of Lower Genital Tract Disease, 2022, 26, 250-257.	0.9	17
118	Oestrogen and progesterone receptors in the human vagina during the menstrual cycle, pregnancy and postmenopause. Maturitas, 1993, 16, 139-144.	1.0	16
119	Hyperglycemia in postmenopausal women screened for the metabolic syndrome is associated to increased sexual complaints. Gynecological Endocrinology, 2010, 26, 86-92.	0.7	16
120	Resilience and related factors during female Ecuadorian mid-life. Maturitas, 2012, 72, 152-156.	1.0	16
121	Inhaled intrapartum analgesia using a 50–50Â% mixture of nitrous oxide–oxygen in a low-income hospital setting. Archives of Gynecology and Obstetrics, 2012, 286, 627-631.	0.8	16
122	The metabolic syndrome and its components in postmenopausal women. Gynecological Endocrinology, 2013, 29, 563-568.	0.7	16
123	Interventions to reduce the risk of ovarian and fallopian tube cancer: A European Menopause and Andropause Society Position Statement. Maturitas, 2017, 100, 86-91.	1.0	16
124	Pregnancy outcomes in younger and older adolescent mothers with severe preeclampsia. Adolescent Health, Medicine and Therapeutics, 2017, Volume 8, 81-86.	0.7	16
125	Uterine or paracervical lidocaine application for pain control during intrauterine contraceptive device insertion: a meta-analysis of randomised controlled trials. European Journal of Contraception and Reproductive Health Care, 2018, 23, 207-217.	0.6	16
126	Sunlight, the vitamin D endocrine system, and their relationships with gynaecologic cancer. Maturitas, 2008, 59, 101-113.	1.0	15

#	Article	IF	CITATIONS
127	First trimester serum levels of 25-hydroxyvitamin D, free β-human chorionic gonadotropin, and pregnancy-associated plasma protein A in Spanish women. Gynecological Endocrinology, 2011, 27, 1061-1064.	0.7	15
128	Assessment of follicular fluid leptin levels and insulin resistance asÂoutcome predictors in womenÂundergoing inÂvitro fertilization–intracytoplasmic sperm injection. Fertility and Sterility, 2014, 102, 1619-1625.	0.5	15
129	EMAS position statement: Fertility preservation. Maturitas, 2014, 77, 85-89.	1.0	15
130	Effect of programmed exercise on perceived stress in middle-aged and old women: A meta-analysis of randomized trials. Maturitas, 2018, 114, 1-8.	1.0	15
131	Uterine fibroids and preterm birth risk: A systematic review and metaâ€analysis. Journal of Obstetrics and Gynaecology Research, 2020, 46, 1711-1727.	0.6	15
132	Studies on human prolactin physiology. Life Sciences, 1974, 15, 599-616.	2.0	14
133	Serum prolactin and thyrotrophin responses to thyrotrophin-releasing hormone at different times of the day in normal women. European Journal of Endocrinology, 1981, 97, 7-11.	1.9	14
134	Vitamin D and adolescent health. Adolescent Health, Medicine and Therapeutics, 2010, 1, 1.	0.7	14
135	Systematic review and meta-analysis regarding the association of endometriosis and preeclampsia in women conceiving spontaneously or through assisted reproductive technology. Pregnancy Hypertension, 2018, 14, 213-221.	0.6	14
136	Vitamin D, menopause, and aging: <i>quo vadis</i> ?. Climacteric, 2020, 23, 123-129.	1.1	14
137	Fragility fracture risk and skeletal muscle function. Climacteric, 2016, 19, 37-41.	1.1	13
138	Detection of Adverse Perinatal Outcomes at Term Delivery Using Ultrasound Estimated Percentile Weight at 35 Weeks of Gestation: Comparison of Five Fetal Growth Standards. Fetal Diagnosis and Therapy, 2020, 47, 104-114.	0.6	13
139	Clinical experiences with drospirenone: From reproductive to postmenopausal years. Maturitas, 2008, 60, 78-91.	1.0	12
140	Metabolic and hormonal parameters in post-menopausal women 10 years after transdermal oestradiol treatment, alone or combined to micronised oral progesterone. Gynecological Endocrinology, 2011, 27, 156-162.	0.7	12
141	Modification of the hand-held Vscan ultrasound and verification of its performance for transvaginal applications. Ultrasonics, 2013, 53, 17-22.	2.1	12
142	Assessment of obstructive sleep apnea-hypopnea syndrome risk at the end of pregnancy using the Berlin Questionnaire. Gynecological Endocrinology, 2015, 31, 715-719.	0.7	12
143	Evaluation of sexuality in a Paraguayan mid-aged female urban population using the six-item Female Sexual Function Index. Climacteric, 2016, 19, 256-260.	1.1	12
144	Evaluation of depressive symptoms in mid-aged women: report of a multicenter South American study. Menopause, 2017, 24, 1282-1288.	0.8	12

#	Article	IF	CITATIONS
145	Lower placental growth factor and higher free β-hCG and PAPP-A levels in the fetal circulation of near-term pregnancies complicated with severe preeclampsia. Gynecological Endocrinology, 2017, 33, 79-81.	0.7	12
146	Application of the 21-item Vulvovaginal Symptoms Questionnaire in postmenopausal Spanish women. Menopause, 2017, 24, 1295-1301.	0.8	12
147	Validation of the Six-item Female Sexual Function Index in Middle-Aged Brazilian Women. Revista Brasileira De Ginecologia E Obstetricia, 2019, 41, 432-439.	0.3	12
148	Perimenopause, body fat, metabolism and menopausal symptoms in relation to serum markers of adiposity, inflammation and digestive metabolism. Journal of Endocrinological Investigation, 2020, 43, 809-820.	1.8	12
149	Pituitary hormonal response to the orthopramides clebopride, bromopride, metoclopramide, and sulpiride. Fertility and Sterility, 1982, 37, 445-447.	0.5	11
150	Evaluation of the presence and severity of menopausal symptoms among postmenopausal women screened for the metabolic syndrome. Gynecological Endocrinology, 2014, 30, 918-924.	0.7	11
151	Erythrocyte folate content and serum folic acid and homocysteine levels in preeclamptic primigravidae teenagers living at high altitude. Archives of Gynecology and Obstetrics, 2013, 288, 1011-1015.	0.8	10
152	Ulipristal acetate in the management of symptomatic uterine fibroids: facts and pending issues. Climacteric, 2015, 18, 177-181.	1.1	10
153	Polymorphisms of the FTO and MTHFR genes and vascular, inflammatory and metabolic marker levels in postmenopausal women. Journal of Endocrinological Investigation, 2016, 39, 885-890.	1.8	10
154	Systematic review and meta-analysis of Spanish studies regarding the association between maternal 25-hydroxyvitamin D levels and perinatal outcomes. Gynecological Endocrinology, 2018, 34, 987-994.	0.7	10
155	Vaginal collagen I and III changes after carbon dioxide laser application in postmenopausal women with the genitourinary syndrome: a pilot study. Climacteric, 2022, 25, 186-194.	1.1	10
156	Pituitary responsiveness to gonadotropin-releasing hormone (GnRH) and thyrotropin-releasing hormone (TRH) during different phases of the same cycle of oral contraceptive steroid therapy. Fertility and Sterility, 1982, 37, 767-772.	0.5	9
157	Perceived control over menopausal hot flushes in mid-aged women. Gynecological Endocrinology, 2010, 26, 607-611.	0.7	9
158	Intimate partner violence and psychoemotional disturbance among pregnant women admitted to hospital with prenatal complications. International Journal of Gynecology and Obstetrics, 2012, 118, 194-197.	1.0	9
159	Leptin, vitamin D, and cardiorespiratory fitness as risk factors for insulin resistance in European adolescents: gender differences in the HELENA Study. Applied Physiology, Nutrition and Metabolism, 2014, 39, 530-537.	0.9	9
160	Application of the 10-item Cervantes Scale among mid-aged Ecuadorian women for the assessment of menopausal symptoms. Maturitas, 2014, 79, 100-105.	1.0	9
161	Factors related to muscle strength in postmenopausal women aged younger than 65 years with normal vitamin D status. Climacteric, 2019, 22, 390-394.	1.1	9
162	Menopausal symptoms are associated with non-adherence to highly active antiretroviral therapy in human immunodeficiency virus-infected middle-aged women. Climacteric, 2020, 23, 229-236.	1.1	9

Faustino R Pérez-LÃ³pez

#	Article	IF	CITATIONS
163	Association between depressed mood and sexual function among mid-aged Paraguayan women. Climacteric, 2020, 23, 566-573.	1.1	9
164	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) universal screening in gravids during labor and delivery. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2021, 256, 400-404.	0.5	9
165	Screening of severe acute respiratory syndrome coronavirus-2 infection during labor and delivery using polymerase chain reaction and immunoglobulin testing. Life Sciences, 2021, 271, 119200.	2.0	9
166	Maternal plasma and amniotic fluid coenzyme Q10 levels in preterm and term gestations: a pilot study. Archives of Gynecology and Obstetrics, 2011, 283, 67-71.	0.8	8
167	EMAS position statement: Late parenthood. Maturitas, 2013, 76, 200-204.	1.0	8
168	The severe acute respiratory syndrome due to coronavirus 2 (SARS-CoV-2) infection and the climacteric woman. Climacteric, 2020, 23, 525-527.	1.1	8
169	Lack of correlation between first trimester maternal serum 25-hydroxyvitamin D levels and ultrasound measured crown-rump length and nuchal translucency. Archives of Gynecology and Obstetrics, 2011, 284, 1585-1588.	0.8	7
170	Adipocytokines, Metabolic Syndrome, and Exercise. International Journal of Endocrinology, 2014, 2014, 1-3.	0.6	7
171	EMAS position statement: Menopause for medical students. Maturitas, 2014, 78, 67-69.	1.0	7
172	Increased mood symptoms in postmenopausal women related to the polymorphism rs743572 of the CYP17 A1 gene. Gynecological Endocrinology, 2016, 32, 827-830.	0.7	7
173	The effect of consuming milk and related products during human pregnancy over birth weight and perinatal outcomes: A systematic review and meta-analysis. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2020, 251, 235-245.	0.5	7
174	Handgrip strength, dynapenia, and related factors in postmenopausal women. Menopause, 2022, 29, 16-22.	0.8	7
175	Hormonal contraceptives and the risk of suicide: a systematic review and meta-analysis. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2020, 251, 28-35.	0.5	7
176	Etiopathogenesis of ovarian cancer. An inflamm-aging entity?. Gynecologic Oncology Reports, 2022, 42, 101018.	0.3	7
177	Beliefs regarding menopausal hot flushes among climacteric women as assessed with the Hot Flush Beliefs Scale. Maturitas, 2010, 66, 298-304.	1.0	6
178	Body mass index and its correlation to metabolic and hormone parameters in postmenopausal Spanish women. Gynecological Endocrinology, 2011, 27, 678-684.	0.7	6
179	EMAS position statement: The management of postmenopausal women with vertebral osteoporotic fracture. Maturitas, 2014, 78, 131-137.	1.0	6

180 The Metabolic Syndrome in Mid-Aged Women. , 2017, , 141-158.

#	Article	IF	CITATIONS
181	Dynapenia and Sarcopenia During Female Midlife. , 2017, , 317-331.		6
182	Vulvodynia: A disease commonly hidden in plain sight. Case Reports in Women's Health, 2018, 20, e00079.	0.2	6
183	Assessing fatal cardiovascular disease risk with the SCORE (Systematic Coronary Risk Evaluation) scale in post-menopausal women 10 years after different hormone treatment regimens. Gynecological Endocrinology, 2010, 26, 533-538.	0.7	5
184	The B-Lynch technique for the management of intraoperative uterine atony. Journal of Obstetrics and Gynaecology, 2012, 32, 338-341.	0.4	5
185	Surgical prevention of epithelial ovary cancer without oophorectomy: changing the future. Climacteric, 2016, 19, 417-418.	1.1	5
186	Umbilical cord plasma interferon-induced protein 10 (IP-10) and interferon-induced T-cell alpha chemoattractant (ITAC) levels are lower in women with severe preeclampsia. Journal of Perinatal Medicine, 2016, 44, 291-4.	0.6	5
187	Systematic review and meta-analysis of the effects of treatment modalities for vestibulodynia in women. European Journal of Contraception and Reproductive Health Care, 2019, 24, 337-346.	0.6	5
188	A cohort study of fetal growth in twin pregnancies by chorionicity: comparison with European and American standards. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2020, 253, 238-248.	0.5	5
189	Preeclampsia and gestational hypertension are associated to low maternal circulating kisspeptin levels: a systematic review and meta-analysis. Gynecological Endocrinology, 2021, 37, 1055-1062.	0.7	5
190	Rethinking elective bilateral oophorectomy at the time of hysterectomy for benign disease. Maturitas, 2013, 76, 109-110.	1.0	4
191	Maternal serum 25-hydroxyvitamin D and C-reactive protein levels in pregnancies complicated with threatened preterm labour. Gynecological Endocrinology, 2016, 32, 777-781.	0.7	4
192	Validation of the 10-item Cervantes Scale in middle-aged Portuguese women: paper-and-pencil and online format assessment of menopause-related symptoms. Menopause, 2019, 26, 203-210.	0.8	4
193	Prediction of Large for Gestational Age by Ultrasound at 35 Weeks and Impact of Ultrasound-Delivery Interval: Comparison of 6 Standards. Fetal Diagnosis and Therapy, 2021, 48, 15-23.	0.6	4
194	Vitamin D, sunlight and longevity. Minerva Endocrinologica, 2011, 36, 257-66.	1.7	4
195	Metformin treatment and evolution of endometrial cancer. Climacteric, 2014, 17, 207-9.	1.1	4
196	Effect of prospidine administered at different times of the day on the development and growth of N-nitrosomethylurea-induced mammary tumors in Wistar ratsâ~†. Cancer Letters, 1984, 24, 111-118.	3.2	3
197	Effects of tamoxifen on endometrial estrogen and progesterone receptor concentrations in women with fibrocystic disease of the breast. Gynecological Endocrinology, 1993, 7, 185-189.	0.7	3
198	Low maternal vitamin D status during pregnancy requires appropriate therapeutic intervention. International Journal of Gynecology and Obstetrics, 2012, 116, 4-5.	1.0	3

#	Article	IF	CITATIONS
199	Menopausal hormone therapy and ovarian cancer: Putting risk into perspective. Maturitas, 2015, 81, 3-4.	1.0	3
200	Epirubicin dose and sequential hormonal therapy—Mature results of the HMFEC randomised phase III trial in premenopausal patients with node positive early breast cancer. European Journal of Cancer, 2016, 60, 146-153.	1.3	3
201	Polymorphism of the THOC5 of the transcription/export multiprotein complex and its correlation with the lipid and metabolic profile in middle-aged women. Gynecological Endocrinology, 2020, 36, 243-246.	0.7	3
202	Severe acute respiratory syndrome coronavirus 19 and human pregnancy. Gynecological Endocrinology, 2020, 36, 277-278.	0.7	3
203	Prediction of Late-Onset Small for Gestational Age and Fetal Growth Restriction by Fetal Biometry at 35 Weeks and Impact of Ultrasound–Delivery Interval: Comparison of Six Fetal Growth Standards. Journal of Clinical Medicine, 2021, 10, 2984.	1.0	3
204	Preeclampsia negatively affects future maternal metabolic and endocrine outcomes. Gynecological Endocrinology, 2021, 37, 773-774.	0.7	3
205	Stimulatory effect of clebopride on human prolactin secretion. Fertility and Sterility, 1980, 34, 452-5.	0.5	3
206	Vulvovaginal atrophy management with a laser: the placebo effect or the conditioning Pavlov reflex. Climacteric, 2022, 25, 323-326.	1.1	3
207	Prl, TSH, FSH, β-hCG and oestriol responses to repetitive (triple) LRH/TRH administration in the third trimester of human pregnancy. European Journal of Endocrinology, 1984, 106, 400-404.	1.9	2
208	Hypovitaminosis D during pregnancy: are we ready to recommend vitamin D supplementation?. Gynecological Endocrinology, 2012, 28, 856-858.	0.7	2
209	Maternal adropin levels in patients with gestational diabetes mellitus: a systematic review and meta-analysis. Gynecological Endocrinology, 2022, 38, 105-109.	0.7	2
210	Screening and Management of Female Sexual Dysfunction During the Second Half of Life. , 2019, , 165-185.		2
211	Leukocyte telomere length in women with and without polycystic ovary syndrome: a systematic review and meta-analysis. Gynecological Endocrinology, 2022, 38, 391-397.	0.7	2
212	Personalized Model to Predict Small for Gestational Age at Delivery Using Fetal Biometrics, Maternal Characteristics, and Pregnancy Biomarkers: A Retrospective Cohort Study of Births Assisted at a Spanish Hospital. Journal of Personalized Medicine, 2022, 12, 762.	1.1	2
213	Hormone therapy and the prevention of cardiovascular disease and cognitive decline: Where do we stand?. Maturitas, 2013, 74, 107-108.	1.0	1
214	Climacteric commentaries. Climacteric, 2014, 17, 308-316.	1.1	1
215	Effects of Exercise on Menopausal Prevalent Conditions. , 2019, , 467-484.		1

216 Sporadic Ovarian and Fallopian Tube Cancer in Postmenopausal Women. , 2019, , 79-100.

1

#	Article	IF	CITATIONS
217	Effect of sulpiride on menopausal hot flashes: a randomized, double-blind, placebo-controlled clinical trial. Gynecological Endocrinology, 2020, 36, 247-251.	0.7	1
218	Association of breastfeeding duration with carotid intima-media thickness in later life: a systematic review and meta-analysis. Gynecological Endocrinology, 2021, 37, 778-784.	0.7	1
219	HUMAN PROLACTIN. European Journal of Endocrinology, 1975, 80, S156-S157.	1.9	1
220	Effect of metformin intervention on circulating irisin levels in polycystic ovary syndrome: a systematic review and collaborative meta-analysis. Gynecological Endocrinology, 2021, , 1-6.	0.7	1
221	Maternal serum irisin levels in normotensive and preeclamptic pregnancies: a systematic review and meta-analysis Â. Gynecological Endocrinology, 2022, , 1-8.	0.7	1
222	Low sexual function is associated with menopausal status in mid-aged women with human immunodeficiency virus infection. Menopause, 2022, Publish Ahead of Print, 317-326.	0.8	1
223	Adherence to osteoporosis medications. Climacteric, 2012, 15, 100-2.	1.1	1
224	Vitamin E supplementation improves testosterone, glucose- and lipid-related metabolism in women with polycystic ovary syndrome: a meta-analysis of randomized clinical trials. Gynecological Endocrinology, 0, , 1-10.	0.7	1
225	Female sexual function before and during the severe acute respiratory syndrome coronavirus-2 pandemic: a systematic review and Meta-analysis of longitudinal studies. Gynecological Endocrinology, 2022, 38, 632-638.	0.7	1
226	Tamoxifen and breast cancer. Gynecological Endocrinology, 1996, 10, 104-104.	0.7	0
227	Optimización del manejo de la mujer osteoporótica en la consulta de ginecologÃa. Progresos En Obstetricia Y Ginecologia, 2009, 52, 227-237.	0.0	0
228	Human Pregnancy and Parturition Clinical Management. Obstetrics and Gynecology International, 2010, 2010, 1-2.	0.5	0
229	Effect of intravenous hydralazine infusion on maternal plasma nitric oxide levels in gestations complicated with severe preeclampsia: a pilot study. Archives of Gynecology and Obstetrics, 2012, 285, 1183-1187.	0.8	0
230	Relationship between body composition, physical fitness and urinary incontinence in non-institutionalized postmenopausal women: the elderly EXERNET multicentre study. Maturitas, 2015, 81, 127.	1.0	0
231	Non-hormonal management of menopausal vasomotor symptoms: Psychosocial interventions. Maturitas, 2015, 82, 444-445.	1.0	0
232	Reply to the Letter to the Editor: A rebuttal: FSFI questionnaire does not assess female sexual function, by V. Puppo and G. Puppo. Maturitas, 2016, 83, 95-96.	1.0	0
233	Bisphosphonates or denosumab discontinuation and risk of fractures: Response to the Letter by Anastasilakis et al Maturitas, 2017, 102, 76-77.	1.0	0
234	The metabolic syndrome and diabetes are not synonymous. Climacteric, 2019, 22, 425-425.	1.1	0

#	Article	IF	CITATIONS
235	Conventional ovarian cancer screening does not reduce its related mortality in postmenopausal women. Climacteric, 2011, 14, 605-6.	1.1	0
236	Plasma homocysteine levels and handgrip strength in postmenopausal women. Climacteric, 2022, , 1-6.	1.1	0